

DOOGAR & ASSOCIATES

Chartered Accountants

Limited Review Report

The Board of Directors

Poly Medicure Limited
1st Floor, 12, Sant Nagar,
East of Kailash,
New Delhi – 110 065.

Dear Sirs,

1. We have reviewed the accompanying statement of unaudited financial results of M/s Poly Medicure Limited (the 'Company') for the quarter ended 30th June, 2013 except for the disclosures regarding "Promoters' shareholding" and "Promoters and promoters group shareholding" which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on this financial statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, "Engagements to Review Financial Statements" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results of the company prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **Doogar & Associates**
Chartered Accountants
(Regn. No. 000561N)



(Signature)
(M. S. Agarwal)

Partner

Mem. No.: 086580

Place: New Delhi

Date: 31.07.2013

Part I

₹ in lacs

	Particulars	Quarter ended			Year Ended
		30.06.2013	31.03.2013	30.06.2012	31.03.2013
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income from operations				
a	Net sales / income from operations (net of excise duty)	6,782.96	6,843.79	5,658.71	24,755.62
b	Other operating income	282.86	67.87	119.30	468.17
	Total income from operations (net)	7,065.82	6,911.66	5,778.01	25,223.79
2	Expenses				
a	Cost of materials consumed	2,214.03	2,177.03	1,735.95	7,932.77
b	Purchases of stock-in-trade	173.42	145.06	131.14	501.08
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	(161.46)	(59.69)	51.22	(110.54)
d	Employee benefits expense	1,169.38	1,110.79	946.79	4,023.78
e	Depreciation and amortisation expense	309.88	299.71	281.04	1,182.06
f	Other expenses	1,833.65	1,841.93	2,022.18	7,761.45
	Total expenses	5,538.90	5,514.83	5,168.32	21,290.60
3	Profit from operations before other income, finance costs and exceptional items (1-2)	1,526.92	1,396.83	609.69	3,933.19
4	Other income	15.46	2.57	10.78	36.76
5	Profit from ordinary activities before finance costs and exceptional items (3 + 4)	1,542.38	1,399.40	620.47	3,969.95
6	Finance costs	139.94	57.72	198.22	589.78
7	Profit from ordinary activities after finance costs but before exceptional items (5 - 6)	1,402.44	1,341.68	422.25	3,380.17
8	Exceptional items	-	-	-	-
9	Profit from ordinary activities before tax (7 + 8)	1,402.44	1,341.68	422.25	3,380.17
10	Tax expense	447.65	416.31	117.54	977.26
11	Net Profit from ordinary activities after tax (9 - 10)	954.79	925.37	304.71	2,402.91
12	Extraordinary items	-	-	-	-
13	Net Profit for the period (11 + 12)	954.79	925.37	304.71	2,402.91
14	Paid-up equity share capital (Face Value of ₹ 10 each)	1,101.25	1,101.25	1,101.25	1,101.25
15	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	10,002.73
16	Earnings per share (before extraordinary items) (not annualised) :				
	Basic (₹)	8.67	8.40	2.77	21.82
	Diluted (₹)	8.66	8.39	2.76	21.79



Handwritten signature


Part II - Select information for the Quarter ended June 30, 2013

A	PARTICULARS OF SHAREHOLDING				
1	Public shareholding				
	Number of shares	5,649,781	5,649,781	5,649,781	5,649,781
	Percentage of shareholding	51.30%	51.30%	51.30%	51.30%
2	Promoters and Promoter Group Shareholding				
	a) Pledged / Encumbered				
	Number of shares	-	-	-	-
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-
	Percentage of shares (as a % of the total share capital of the company)	-	-	-	-
	b) Non - encumbered				
	Number of shares	5,362,719	5,362,719	5,362,719	5,362,719
	Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%
	Percentage of shares (as a % of the total share capital of the company)	48.70%	48.70%	48.70%	48.70%
B	Investor Complaints				
	Pending at the beginning of the quarter	Nil			
	Received during the quarter	1			
	Disposed of during the quarter	1			
	Remaining unresolved at the end of the quarter	Nil			

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 31st July 2013.
- Further issue of 11012500 equity shares of ₹ 10 each issued under Bonus issue made by the company have been listed and admitted to dealings on NSE and BSE from 16th July 2013. Since the paid-up capital of the company has increased post bonus after the quarter ended 30th June 2013, EPS as reported above has not been restated.
- The Company is primarily engaged in the business of manufacture and sale of "Medical Devices" and, hence, there is no reportable segments as per Accounting Standard-17 issued by ICAI.
- In view of option allowed by the Ministry of Corporate Affairs vide its notification dated 29th December 2011 on AS 11, the exchange differences arising on reporting of long term foreign currency monetary items at rates different from those at which they were initially recorded have been accumulated in a "Foreign Currency Monetary Items Translation Difference Account" to be amortised over the balance period of such long term assets or liabilities. Pursuant to such adoption, a sum of ₹ 266.73 lacs is remained to be amortised over the balance period of such assets or liabilities.
- The statutory Auditors have carried out the limited review of the above results.
- The figures for the corresponding periods have been regrouped / rearranged, wherever necessary, to make them comparable.

By order of the Board



Place : New Delhi

Himanshu Baid

Date : 31.07.2013

Managing Director

